Searchable abstracts of presentations at key conferences in endocrinology

ea0091wf3 | Workshop F: Disorders of the parathyroid glands, calcium metabolism and bone | SFEEU2023

Differentiating Primary Hyperparathyroidism from Familial Hypocalciuric Hypercalcaemia Can Be Difficult: A Misleading Urinary Calcium to Creatinine Clearance Ratio

G Mills Edouard , J Hadjiminas Dimitri , Abbara Ali , Behary Preeshila , Cox Jeremy , N Comninos Alexander

Case: We report a 79-year-old female who was referred to our Endocrine Bone Unit with osteoporosis, which was initially treated with Alendronate (but poorly tolerated due to dyspepsia) followed by annual Zoledronate infusions. Her bone history was significant for a proximal humeral fragility fracture 30-years previously. She was an ex-smoker, had limited dietary calcium intake, and had a brother with osteoporosis. DEXA demonstrated T scores at lumbar spine -1.8, total hip -2.0...

ea0094oc4.4 | Reproductive Endocrinology | SFEBES2023

Intranasal kisspeptin: a novel, effective and non-invasive approach to stimulate reproductive hormones in patients with reproductive disorders

G Mills Edouard. , Delli Virginia , Chachlaki Konstantina , Silva Mauro SB. , Decoster Laurine , Ternier Gaetan , Thurston Layla , Phylactou Maria , Patel Bijal , Yang Lisa , Clarke Sophie A. , Alexander Emma , Choudhury Muhammad , Bech Paul , Abbara Ali , Swedrowska Magda , Forbes Ben , Giacobini Paolo , Prevot Vincent , Comninos Alexander N. , Dhillo Waljit S.

Background: Kisspeptin is a potent regulator of GnRH neurons with potential to treat reproductive and psychosexual disorders. However, administration is limited to the subcutaneous or intravenous routes. These invasive routes limit clinical development. Herein, we comprehensively examine the translational potential of intranasal kisspeptin administration for the first-time using rodent, human and pharmaceutical studies.Methods:</...

ea0094p371 | Neuroendocrinology and Pituitary | SFEBES2023

GnRH neuronal disruption and hypotestosteronemia in COVID-19

Sauve Florent , Nampoothiri Sreekala , Clarke Sophie , Fernandois Daniela , Fernando Ferreira Coelho Caio , Dewisme Julie , G Mills Edouard , Ternier Gaetan , Cotellessa Ludovica , Iglesias Garcia Cristina , Mueller-Fielitz Helge , Lebouvier Thibaud , Perbet Romain , Florent Vincent , Baroncini Marc , Sharif Ariane , Ereno-Orbea June , Mercado-Gomez Maria , Palazon Asis , Mattot Virginie , Pasquier Florence , Catteau-Jonard Sophie , Martinez-Chantar Maria , Hrabovszky Erik , Jourdain Merce , Deplanque Dominique , Morelli Annamaria , Guarnier Giulia , Storme Laurent , Robil Cyril , Trottein Francois , Nogueiras Ruben , Schwaninger Markus , Pigny Pascal , Poissy Julien , Chachlaki Konstantina , Maurage Claude-Alain , Giacobini Paolo , S Dhillo Waljit , Rasika S , Prevot Vincent

Loss of gonadotropin-releasing hormone (GnRH) and cognitive deficits have recently been demonstrated by our group in conditions including Down syndrome and Alzhiemer’s disease. In some patients with COVID-19, olfactory and cognitive alterations persist, and persistent hypotestosteronemia in SARS-CoV-2-infected men could be a consequence of deficient GnRH. To understand whether neuroinvasion of GnRH system by SARS-CoV-2 could explain some post-COVID symptoms and thus resul...